Company Overview of WavoDyne Therapeutics Inc.
WavoDyne Therapeutics Inc. develops and commercializes therapeutic drugs to treat memory and cognitive disorders resulting from neuroinflammatory processes. The company focuses on preclinical drug discovery efforts and clinical product development programs for neurodegenerative diseases. Its drug candidate is under phase 1 clinical study that includes URMC-099, which targets the treatment of postoperative cognitive dysfunction (POCD) and HIV associated neurocognitive disorders (HAND), as well as cognitive disorders associated with multiple sclerosis and Parkinson’s disease. The company was founded in 2015 and is based in Rochester, New York.
150 Lucius Gordon Drive
Lennox Tech Enterprise Center
Rochester, NY 14586
Founded in 2015
Key Executives for WavoDyne Therapeutics Inc.
WavoDyne Therapeutics Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact WavoDyne Therapeutics Inc., please visit wavodyne.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.